Drug Trial News

RSS

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

17 May 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa formulation used in both ND0612H and ND0612L.

13 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

Modified dosage of clot-busting drug can reduce intracerebral haemorrhage

The safety of a controversial clot-busting drug has been investigated by researchers, who have shown a modified dosage can reduce serious bleeding in the brain and improve survival rates.

11 May 2016

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers.

10 May 2016

Experimental vaccine protects healthy U.S. adults from malaria infection for more than one year

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine.

10 May 2016

Study finds no gender-based differences on use of anticoagulation medications in TAVR patients

A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.

9 May 2016

Women often excluded from type 2 diabetes drug trials

While women who are pregnant, or breastfeeding or who may become pregnant are often excluded from clinical trials for type 2 diabetes drugs, the exclusion is frequently not based on the risk of fetal harm, according to Penn State College of Medicine researchers and may be contributing to the underrepresentation of women in clinical trials and an incomplete understanding of the effects of drugs on women who become pregnant unexpectedly.

6 May 2016

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

5 May 2016

Ebola vaccine shows promise in clinical trials

"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, "With this, a single vaccine could provide lasting protection against Ebola." The infectious disease specialist, who works for the German Center for Infection Research at the University Medical Center Hamburg Eppendorf in Hamburg, led the trial in Hamburg.

4 May 2016

Vernakalant drug more effective than Ibutilide in treating recent-onset atrial fibrillation

Vernakalant, a new drug for treating recent-onset atrial fibrillation, has proved to be considerably more effective than Ibutilide, an established drug in this indication. It was able to normalize patients' heart rhythm more rapidly and with fewer side-effects ocurring. This was revealed by a study conducted at the Department of Emergency Medicine at Medical University of Vienna/General Hospital that has recently been published in "Europace", a journal of the European Society of Cardiology.

2 May 2016

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Adults with asthma who were treated with one-dose dexamethasone in the emergency department had only slightly higher relapse than patients who were treated with a 5-day course of prednisone.

28 Apr 2016

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA.

27 Apr 2016

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.

25 Apr 2016

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies.

22 Apr 2016

Two Ebola vaccine candidates show promise in clinical trial

An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial.

20 Apr 2016

New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

A clinical study evaluating a new hypothesis that an inexpensive drug with a simple treatment regimen can prevent type 1 diabetes will be launched in Dundee tomorrow.

20 Apr 2016

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy.

20 Apr 2016

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.

20 Apr 2016

Drug Trial News

Magic mushroom compound may offer potential new way for antidepressant research

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

Clinical study shows sitagliptin drug not effective in treating NAFLD

Modified dosage of clot-busting drug can reduce intracerebral haemorrhage

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

Experimental vaccine protects healthy U.S. adults from malaria infection for more than one year

Study finds no gender-based differences on use of anticoagulation medications in TAVR patients

Women often excluded from type 2 diabetes drug trials

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Ebola vaccine shows promise in clinical trials

Vernakalant drug more effective than Ibutilide in treating recent-onset atrial fibrillation

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Two Ebola vaccine candidates show promise in clinical trial

New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News